Hemogram and myelogram in progressing non-Hodgkin's lymphomas.

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Non-Hodgkin's lymphomas (NHL) encompass aggressive and indolent subtypes with distinct clinical behaviors.
• Chemotherapy is a primary treatment modality, and understanding treatment response is crucial for patient management.
• Hematological parameters and bone marrow examination (myelogram) provide insights into disease status and treatment effects.

Purpose of the Study:

• To investigate the relationship between hemogram and myelogram parameters before treatment and their correlation with remission or progression 6 months post-chemotherapy in patients with aggressive and indolent NHL.
• To identify prognostic indicators within hematological and bone marrow findings for predicting treatment outcomes in NHL.

Main Methods:

• Multifactorial analysis was employed to study hemogram and myelogram parameters.
• Parameters were assessed before treatment and at 6 months post-chemotherapy (during remission or progression).
• Patients with aggressive and indolent non-Hodgkin's lymphomas were included.

Main Results:

• In indolent NHL, disease progression correlated with bone marrow infiltration, leading to lymphocytosis and a decrease in granulocytic hemopoietic stem cells.
• In aggressive NHL, a lack of remission was associated with decreased hemoglobin and erythroid cells.
• Pre-chemotherapy myelogram findings of anemia and suppressed erythropoiesis were linked to poor prognosis in aggressive NHL.

Conclusions:

• Hematological and bone marrow parameters serve as valuable prognostic indicators in non-Hodgkin's lymphomas.
• Pre-treatment anemia and suppressed erythropoiesis in aggressive NHL suggest a need for intensified chemotherapy.
• Understanding these changes aids in tailoring treatment strategies for improved patient outcomes.